Last reviewed · How we verify

Elbasvir / Grazoprevir Oral Tablet [Zepatier]

University of Maryland, Baltimore · FDA-approved active Small molecule

Elbasvir / Grazoprevir Oral Tablet [Zepatier] is a Direct-acting antiviral (DAA) combination Small molecule drug developed by University of Maryland, Baltimore. It is currently FDA-approved for Chronic hepatitis C virus (HCV) infection, genotypes 1, 4, 5, and 6, Chronic hepatitis C virus infection, genotype 3 (with sofosbuvir). Also known as: Sofosbuvir/Ledipasvir, Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir.

Elbasvir and grazoprevir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS5A and NS3/4A protease, respectively, blocking viral replication.

Elbasvir and grazoprevir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS5A and NS3/4A protease, respectively, blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, genotypes 1, 4, 5, and 6, Chronic hepatitis C virus infection, genotype 3 (with sofosbuvir).

At a glance

Generic nameElbasvir / Grazoprevir Oral Tablet [Zepatier]
Also known asSofosbuvir/Ledipasvir, Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir
SponsorUniversity of Maryland, Baltimore
Drug classDirect-acting antiviral (DAA) combination
TargetHCV NS5A protein and HCV NS3/4A serine protease
ModalitySmall molecule
Therapeutic areaVirology / Hepatology
PhaseFDA-approved

Mechanism of action

Elbasvir is an NS5A inhibitor that prevents HCV protein complex formation and viral assembly. Grazoprevir is an NS3/4A serine protease inhibitor that blocks the cleavage of HCV polyproteins essential for viral replication. Together, they provide a potent combination therapy against HCV with high barrier to resistance.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Elbasvir / Grazoprevir Oral Tablet [Zepatier]

What is Elbasvir / Grazoprevir Oral Tablet [Zepatier]?

Elbasvir / Grazoprevir Oral Tablet [Zepatier] is a Direct-acting antiviral (DAA) combination drug developed by University of Maryland, Baltimore, indicated for Chronic hepatitis C virus (HCV) infection, genotypes 1, 4, 5, and 6, Chronic hepatitis C virus infection, genotype 3 (with sofosbuvir).

How does Elbasvir / Grazoprevir Oral Tablet [Zepatier] work?

Elbasvir and grazoprevir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS5A and NS3/4A protease, respectively, blocking viral replication.

What is Elbasvir / Grazoprevir Oral Tablet [Zepatier] used for?

Elbasvir / Grazoprevir Oral Tablet [Zepatier] is indicated for Chronic hepatitis C virus (HCV) infection, genotypes 1, 4, 5, and 6, Chronic hepatitis C virus infection, genotype 3 (with sofosbuvir).

Who makes Elbasvir / Grazoprevir Oral Tablet [Zepatier]?

Elbasvir / Grazoprevir Oral Tablet [Zepatier] is developed and marketed by University of Maryland, Baltimore (see full University of Maryland, Baltimore pipeline at /company/university-of-maryland-baltimore).

Is Elbasvir / Grazoprevir Oral Tablet [Zepatier] also known as anything else?

Elbasvir / Grazoprevir Oral Tablet [Zepatier] is also known as Sofosbuvir/Ledipasvir, Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir.

What drug class is Elbasvir / Grazoprevir Oral Tablet [Zepatier] in?

Elbasvir / Grazoprevir Oral Tablet [Zepatier] belongs to the Direct-acting antiviral (DAA) combination class. See all Direct-acting antiviral (DAA) combination drugs at /class/direct-acting-antiviral-daa-combination.

What development phase is Elbasvir / Grazoprevir Oral Tablet [Zepatier] in?

Elbasvir / Grazoprevir Oral Tablet [Zepatier] is FDA-approved (marketed).

What are the side effects of Elbasvir / Grazoprevir Oral Tablet [Zepatier]?

Common side effects of Elbasvir / Grazoprevir Oral Tablet [Zepatier] include Headache, Fatigue, Nausea, Diarrhea, Asthenia.

What does Elbasvir / Grazoprevir Oral Tablet [Zepatier] target?

Elbasvir / Grazoprevir Oral Tablet [Zepatier] targets HCV NS5A protein and HCV NS3/4A serine protease and is a Direct-acting antiviral (DAA) combination.

Related